title: Effects of alendronate on osteoporosis treatment and levels of related cytokines.
abstract: Alendronate regulates the activity of osteoclasts and healing of osteoporosis. This study investigated the effect of alendronate on bone healing and changes in the levels of cytokines. Bilateral ovaries of 10 adult female rabbits were removed surgically in aseptic condition to establish the animal model of osteoporosis. Five rabbits in group A were treated with alendronate (1.15 mg·kg-1·week-1) once a week by a stomach tube, whereas the remaining 5 in group B were treated with physiological saline. The success of the animal model establishment and the efficacy of alendronate treatment were evaluated by the sports ability score and the Basso, Beattie, and Bresnahan (BBB) score; the healing degree of osteoporosis was determined by X-ray analysis and measurement of biomechanical properties; the changes in the levels of related cytokines were measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining. Treatment improved dyskinesia of the animals in group A than that in group B, with significant improvement occurring in the 4th week of treatment. The BBB score of the group A animals revealed movements similar to normal, but that of the group B animals exhibited significant motor disturbance (P < 0.01). X-ray examination showed that with time, the X-ray ratings increased. Measurement of the biomechanical properties further showed that alendronate had a positive effect on osteoporosis healing. The results of ELISA and immunohistochemistry showed that the levels of ALP, BMP-2, bFGF, and IGF-1 were upregulated in group A. In conclusion, alendronate accelerated osteoporosis healing probably via certain cytokine-related mechanism.
authors.affiliation: Department of Orthopedics, Medical College of Nanchang University, Nanchang, Jiangxi, China changtieliu@163.com.
authors.forename: C T
authors.initials: CT
authors.lastname: Liu
authors.affiliation: Department of Neurology, Gaoan People's Hospital, Gaoan, Jiangxi, China.
authors.forename: X J
authors.initials: XJ
authors.lastname: Yuan
authors.affiliation: Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
authors.forename: G C
authors.initials: GC
authors.lastname: Gao
mesh_terms: D019386:Alendronate / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D055396:Bone Morphogenetic Protein 2 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D004195:Disease Models, Animal; D020820:Dyskinesias / Q000188:drug therapy*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D010052:Ovariectomy / Q000009:adverse effects; D011817:Rabbits; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D050071:Bone Density Conservation Agents; D055396:Bone Morphogenetic Protein 2; D016207:Cytokines; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; D019386:Alendronate